Home
About HCM
Diagnosis
Diagnostic Imaging
Treatment
Learning Hub
Tools & Resources
SmPC
Home
About HCM
Diagnosis
Diagnostic Imaging
Treatment
Learning Hub
Tools & Resources
SmPC
Home
About HCM
Diagnosis
Diagnostic Imaging
Treatment
Learning Hub
Tools & Resources
SmPC
Home
About HCM
Diagnosis
Diagnostic Imaging
Treatment
Learning Hub
Tools & Resources
SmPC
Home
About HCM
Diagnosis
Diagnostic Imaging
Treatment
Learning Hub
Tools & Resources
SmPC
Home
About HCM
Diagnosis
Diagnostic Imaging
Treatment
Learning Hub
Tools & Resources
SmPC
Home
About HCM
Diagnosis
Diagnostic Imaging
Treatment
Learning Hub
Tools & Resources
SmPC
Home
About HCM
Diagnosis
Diagnostic Imaging
Treatment
Learning Hub
Tools & Resources
SmPC

Diagnosis

On this page

When to suspect HCM

HCM should be suspected in a patient who presents with nonspecific but limiting cardiac symptoms. It should also be considered in individuals with a history of a previous cardiac event or a family history of HCM. Additionally, the presence of a heart murmur or abnormalities on an ECG may raise suspicion of HCM and warrant further evaluation33.

Symptoms & potential indicators

Suspicion of HCM can be raised based on clinical symptoms, family history, abnormalities detected on an electrocardiogram, or findings from a routine medical examination34

Symptoms 

HCM is a heart condition with highly variable manifestations, including morphological, functional, and clinical characteristics. This means that patients may present with a wide range of symptoms, from mild discomfort to more severe manifestations.

Symptoms may appear as one or more of the following35-36:

  • Parents with HCM or a history of sudden/unexpected death.
  • Reviewing the family history over three to four generations can help identify HCM and family members who may be at risk12.
DNA
  • Abnormal ECG findings are observed in approximately 90–96% of patients with HCM, and no specific ECG pattern is pathognomonic37-38.
  • Common abnormalities include39:
    • ST-T wave changes
    • Wide R waves (V5 and V6)
    • Pathological Q waves
    • Repolarization changes (strain pattern)
    • Deep S waves (V1 and V2)
    • P wave abnormalities
    • Increased QRS voltages
    • Deep T-wave inversion

Patients with classic HCM may present with a systolic ejection murmur, a prominent apical impulse, an abnormal carotid pulse, and a fourth heart sound34. The murmur is best heard over the lower left sternal border and becomes louder with manoeuvres that decrease preload (e.g., Valsalva or standing from the squatting position)40.

First-line tests

HCM is characterized by left ventricular hypertrophy (LVH) that cannot be explained by another cardiac, systemic, or metabolic disease34. Echocardiography is the fundamental imaging modality for most patients34.

septale

 Journal of the American Collega of Cardiology, Vol 54, Issue 3, Bos JM et al, Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy, pages 201-2011, Copyright 2009, with permission of Elsevier

2D echocardiography is used to characterize all walls of the left ventricle.

  • Wall thickness should be evaluated in all segments of the LV, from base to apex41.
  • 2D echocardiography is particularly useful because LVH is often asymmetric or confined to the apex42.

Parasternal Short-Axis View (PSAX)

The PSAX view, with orthogonal beam alignment, provides the most accurate measurement as it avoids oblique orientation, which can lead to overestimation of wall thickness43.

Parasternal Long-Axis View (PLAX)

The PLAX view is useful for examining the apex and, if needed, the right ventricle44-12.

  • LVH can also be measured with M-mode echocardiography, although it is limited because it only assesses the basal segments of the interventricular septum and posterior wall41.
  • Features to look for on M-mode suggestive of HCM45:
    • Asymmetric septal hypertrophy
    • Systolic anterior motion (SAM) of the mitral valve
    • Small LV cavity
    • Septal immobility
    • Premature aortic valve closure

Advanced imaging

In some cases, HCM can cause left ventricular outflow tract (LVOT) obstruction due to narrowing of the LVOT34. This may lead to elevated intracavitary pressures, mitral regurgitation, myocardial ischemia, and other abnormalities34.

Imaging approaches to determine LVOT obstruction

2D echocardiography or Doppler echocardiography can help determine the cause and severity of left ventricular outflow tract (LVOT) obstruction12.

  • Measurement of late systolic peak velocity46.
  • Measurement of the maximal instantaneous gradient derived from peak velocity44-47.
Special cases of LVOT obstruction
  • Mid-ventricular obstruction occurs in approximately 10% of patients with HCM48.
  • Can occur in ventricles with hyperdynamic function and/or concentric hypertrophy44.
  • Usually observed in older patients with a sigmoid septum44.
Alternative imaging

When transthoracic echocardiography (TTE) is inadequate, consider transoesophageal echocardiography (TOE) or cardiac magnetic resonance imaging (CMR). In symptomatic patients with inconclusive noninvasive imaging, left and right heart catheterisation may be considered to assess LVOT gradient and filling pressures49.

Doppler Mode Selection

The choice of Doppler mode depends on the imaging objective44:

  • Site of obstruction: Pulsed-wave Doppler (PW)
  • Degree of obstruction: Continuous-wave Doppler (CW)
Provocative testing to detect LVOT obstruction
  • Detection and quantification of LVOT obstruction should be performed both at rest and with provocation, using manoeuvres such as the Valsalva manoeuvre or standing up from a squatting position34-46.
  • This is particularly important for patients whose LVOT gradient at rest or under standard echocardiographic provocation is <50 mmHg34.
  • Patients with low resting gradients (<30 mmHg) may demonstrate obstructive gradients with provocation; those with modest resting gradients (30–49 mmHg) can develop significant gradients (≥50 mmHg) during exercise50-51-52-53.
Provocation based on Resting Gradient
provoc

Many patients with HCM do not demonstrate LVOT obstruction at rest; therefore, provocation is recommended when the resting gradient is <50 mmHg.

External resources

Consult the external clinical guidelines below for additional references12.

Clinical diagnosis flowchart

This flowchart illustrates the key steps in evaluating and diagnosing cardiomyopathies, including symptom assessment, family history, physical examination, ECG, imaging, and further testing when needed12.

Patient testimonials

HCM can affect daily life in many ways, both physically and emotionally. Patient stories offer a unique perspective on living with HCM, illustrating the challenges, adaptations, and strategies people use to manage their condition.

Next step: Treatment options

Learn more about the role of cardiac myosin inhibition
within today’s therapeutic landscape for HCM.

Discover page >

Imaging modules

Learn how to apply imaging techniques to identify
and assess HCM in clinical practice.

Discover page >

  1. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(39):3948–4046. doi:10.1093/eurheartj/ehad194
  1. Mitchell CC, Frye C, Jankowski M, et al. A practical approach to echocardiographic imaging in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2023;36(9):913-932. DOI: 10.1016/j.echo.2023.04.020
  2. Ommen SR et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):e159-240. DOI: 10.1016/j.jacc.2020.08.045
  3. Argulian E et al. Misconceptions and Facts About Hypertrophic Cardiomyopathy. Am J Med. 2016;129(2):148-52. DOI: 10.1016/j.amjmed.2015.07.035
  4. Wexler RK et al. Cardiomyopathy: an overview. Am Fam Physician. 2009;79(9):778-84. PMID: 20141097 PMCID: PMC2999879
  5. Finocchiaro G, et al. Electrocardiographic presentation and outcome in hypertrophic cardiomyopathy. Heart Rhythm. 2020;17(1):142–161. DOI: 10.1016/j.hrthm.2019.07.016.
  6. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal. 2023;44(39):3948–4046. DOI: 10.1093/eurheartj/ehad194
  7. Antunes MO, Scudeler TL. Hypertrophic cardiomyopathy [published correction appears in Int J Cardiol Heart Vasc. 2020 Nov 18;31:100676]. Int J Cardiol Heart Vasc. 2020;27:100503. DOI: 10.1016/j.ijcha.2020.100503
  8. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(39):3948–4046. DOI: 10.1093/eurheartj/ehad194
  9. Pantazis A,et al. Diagnosis and management of hypertrophic cardiomyopathy. Echo Res Pract. 2015;2(1):R45-53. DOI: 10.1530/ERP-15-0007
  10. Losi MA et al. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound. 2010;8:7. DOI:10.1186/1476-7120-8-7
  11. [1] Makavos G et al. Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment. Heart Fail Rev. 2019;24(4):439-59. DOI: 10.1007/s10741-019-09775-4
  12. Nagueh SF et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2011;24(5):473-98. DOI: 10.1016/j.echo.2011.03.006
  13. Losi MA et al. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound. 2010;8:7. DOI: 10.1186/1476-7120-8-7
  14. Maron MS et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outfl ow tract obstruction. Circulation. 2006;114(21):2232-9. DOI: 10.1161/CIRCULATIONAHA.106.644682
  15. Gersh BJ et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212-60. DOI: 10.1016/j.jacc.2011.06.011
  16. Makavos G et al. Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment. Heart Fail Rev. 2019;24(4):439-59. DOI: 10.1007/s10741-019-09775-4
  17. Elliott PM et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. DOI: 10.1093/eurheartj/ehu284
  18. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. DOI: 10.1093/eurheartj/ehad194
  19. Arbelo E, Protonotarios A, Gimeno JR, et al. Eur Heart J. 2023;44(39):3948–4046. DOI: 10.1093/eurheartj/ehad194
  20. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. DOI: 10.1056/NEJMoa021332
  21. N Engl J Med. 2003;348(4):295–303. DOI: 10.1056/NEJMoa021332t

 

CV-BE-2600012 – 01/2026